Mining of protein based biomarkers for type 2 diabetes mellitus

Pakistan Journal of Pharmaceutical Sciences

Volumn 25, Issue 4, 2012, Pages 889-901

  Khan, Abdul Rehman ^a,b   Awan, Fazli Rabbi ^a  

^a NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

^b UNIVERSITY OF AZAD JAMMU AND KASHMIR   (Pakistan)

Author keywords

2DGE; Biomarker; Diabetes; LC MS; Proteomics; Serum

Indexed keywords

ADIPONECTIN; ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ALPHA ACTININ; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBONATE DEHYDRATASE; CHAPERONIN CONTAINING TCP1; COMPLEMENT COMPONENT C6; CYSTATIN C; DESMIN; FATTY ACID BINDING PROTEIN; FERRITIN; FETUIN A; GLYCOGEN PHOSPHORYLASE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2 RECEPTOR; LEPTIN; PREALBUMIN; RETINOL BINDING PROTEIN; TRANSFERRIN; UVOMORULIN; VERY LOW DENSITY LIPOPROTEIN; ANTIDIABETIC AGENT; PLASMA PROTEIN;

AGE; DNA SEQUENCE; FAMILY HISTORY; HEREDITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HYDROPHOBICITY; ISOELECTRIC POINT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERSONALIZED MEDICINE; PH; POLYPHARMACY; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; ANIMAL; BLOOD; DATA MINING; DRUG DESIGN; METHODOLOGY; PROGNOSIS;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PROTEINS; DATA MINING; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; PROGNOSIS; PROTEOMICS;

EID: 84871898243     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. ADA (2012). Diagnosis and classification of diabetes mellitus. Diabetes Care, 35(Suppl 1): S64-S71.
2. Ackermann BL and Berna MJ (2007). Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev. Proteomics, 4: 175-186.
3. Aebersold R and Mann M (2003). Mass spectrometrybased proteomics. Nature, 422: 198-207.
4. Ahmed N, Barker G, Oliva K, Garfin D, Talmadge K, Georgiou H, Quinn M and Rice G (2003). An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics, 3: 1980-1987.
5. Ahn SM and Simpson RJ (2007). Body fluid proteomics: Prospects for biomarker discovery. Proteomics Clin. Appl., 1: 1004-1015.
6. Anderson L (2005). Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol., 563: 23-60.
7. Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Mullner S, Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert K, Rothe G, Stockinger H, Tarnok A, Taussig MJ, Thiel A, Thiery J, Ueffing M, Valet G, Vandekerckhove J, Verhuven W, Wagener C, Wagner O and Schmitz G (2009). In: Clin. Chem. Lab. Med., 47: 724-744.
8. Bahceci M, Tuzcu A, Ogun C, Canoruc N, Iltimur K and Aslan C (2005). Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease? J. Endocrinol. Invest., 28: 145-150.
9. Basit A and Shera AS (2008). Prevalence of metabolic syndrome in Pakistan. Metab. Syndr. Relat. Disord., 6: 171-175.
10. Bennett CM, Guo M and Dharmage SC (2007). HbA(1c) as a screening tool for detection of Type 2 diabetes: A systematic review. Diabet. Med., 24: 333-343.
11. Bonora E and Tuomilehto J (2011). The pros and cons of diagnosing diabetes with A1C. Diabetes Care, 34(Suppl 2): S184-S190.
12. Borrebaeck CA and Wingren C (2009). Transferring proteomic discoveries into clinical practice. Expert Rev. Proteomics, 6: 11-13.
13. Brownlee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414: 813-820
14. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA and Butler PC (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes, 52: 102-110.
15. Chevalier F (2010). Highlights on the capacities of "Gelbased" proteomics. Proteome Sci., 8: 23.
16. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK and Park KS (2006). Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care, 29: 2457-2461.
17. Choi SH, Kwak SH, Youn BS, Lim S, Park YJ, Lee H, Lee N, Cho YM, Lee HK, Kim YB, Park KS and Jang HC (2008). High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus. J. Clin. Endocrinol. Metab., 93: 3142-3148.
18. Colagiuri S and Davies D (2009). The value of early detection of type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes., 16: 95-99.
19. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS and Gregg EW (2006). Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care, 29: 1263-1268.
20. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA and Ezzati M (2011). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 378: 31-40.
21. Donath MY and Shoelson SE (2011). Type 2 diabetes as an inflammatory disease. Nature Review Immunology, 11: 98-107.
22. Duncan MW and Hunsucker SW (2005). Proteomics as a tool for clinically relevant biomarker discovery and validation. Exp. Biol. Med. (Maywood), 230: 808-817.
23. Echan LA, Tang HY, Ali-Khan N, Lee K and Speicher DW (2005). Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics, 5: 3292-3303.
24. Erikstrup C, Mortensen OH, Nielsen AR, Fischer CP, Plomgaard P, Petersen AM, Krogh-Madsen R, Lindegaard B, Erhardt JG, Ullum H, Benn CS and Pedersen BK (2009). RBP-to-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes. Diabetes Obes. Metab., 11: 204-212.
25. Ferraz TP, Fiuza MC, Dos Santos ML, Pontes De Carvalho L and Soares NM (2004). Comparison of six methods for the extraction of lipids from serum in terms of effectiveness and protein preservation. J. Biochem. Biophys. Methods, 58: 187-193.
26. Festa A, D'Agostino R, Jr., Tracy RP and Haffner SM (2002). Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes, 51: 1131-1137.
27. Fu Q, Garnham CP, Elliott ST, Bovenkamp DE and Van Eyk JE (2005). A robust, streamlined, and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophoresis. Proteomics, 5: 2656-2664.
28. Gahagan S and Silverstein J (2003). Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. American Academy of Pediatrics Committee on Native American Child Health. Pediatrics, 112: e328.
29. Ghaffar A, Reddy KS and Singhi M (2004). Burden of non-communicable diseases in South Asia. BJM, 328: 807-10.
30. Goldfine AB, Fonseca V and Shoelson SE (2011). Therapeutic approaches to target inflammation in type 2 diabetes. Clin. Chem., 57: 162-167.
31. Grebe SK and Singh RJ (2011). LC-MS/MS in the Clinical Laboratory - Where to From Here? Clin. Biochem. Rev., 32: 5-31.
32. Grus FH, Joachim SC and Pfeiffer N (2007). Proteomics in ocular fluids. Proteomics Clin. Appl., 1: 876-888.
33. Hanash S (2003). Disease proteomics. Nature, 422: 226-232.
34. Hatunic M, Burns N, Finucane F, Mannion C and Nolan JJ (2005). Contrasting clinical and cardiovascular risk status between early and later onset type 2 diabetes. Diab. Vasc. Dis. Res., 2: 73-75.
35. Herder C, Karakas M and Koenig W (2011). Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin. Pharmacol. Ther., 90: 52-66.
36. Hossain P, Kawar B and El Nahas M (2007). Obesity and diabetes in the developing world - A growing challenge. N. Engl. J. Med., 356: 213-215.
37. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG and Willett WC (2001). Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N. Engl. J. Med., 345: 790-797.
38. Hu S, Loo JA and Wong DT (2006). Human body fluid proteome analysis. Proteomics, 6: 6326-6353.
39. Husebye ES and Anderson MS (2010). Autoimmune polyendocrine syndromes: Clues to type 1 diabetes pathogenesis. Immunity, 32: 479-487.
40. Hwang H, Bowen BP, Lefort N, Flynn CR, De Filippis EA, Roberts C, Smoke CC, Meyer C, Hojlund K, Yi Z and Mandarino LJ (2010). Proteomics analysis of human skeletal muscle reveals novel abnormalities in obesity and type 2 diabetes. Diabetes, 59: 33-42.
41. Inzucchi SE and McGuire DK (2008). New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation, 117: 574-584.
42. Issaq HJ, Xiao Z and Veenstra TD (2007). Serum and plasma proteomics. Chem. Rev., 107: 3601-3620.
43. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR and Shlipak MG (2008). Fetuin-A and incident diabetes mellitus in older persons. JAMA, 300: 182-188.
44. Kay R, Barton C, Ratcliffe L, Matharoo-Ball B, Brown P, Roberts J, Teale P and Creaser C (2008). Enrichment of low molecular weight serum proteins using acetonitrile precipitation for mass spectrometry based proteomic analysis. Rapid Commun. Mass Spectrom., 22: 3255-3260.
45. Kleivi K (2006). Advances in the genetics and epigenetics of gene regulation and human disease. Genome Biol., 7: 325.
46. Klonoff DC (2008). Personalized medicine for diabetes. J. Diabetes Sci. Technol., 2: 335-341.
47. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA and Nathan DM (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 346: 393-403.
48. Koehn J and Krapfenbauer K (2010). Advanced proteomics procedure as a detection tool for predictive screening in type 2 pre-Diabetes. The EPMA Journal, 1: 19-31
49. Kolberg JA, Jorgensen T, Gerwien RW, Hamren S, McKenna MP, Moler E, Rowe MW, Urdea MS, Xu XM, Hansen T, Pedersen O and Borch-Johnsen K (2009). Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care, 32: 1207-1212.
50. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y and Baron AD (2003). Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab., 88: 3082-3089.
51. Koopman RJ, Mainous AG, 3rd, Diaz VA and Geesey ME (2005). Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann. Fam. Med., 3: 60-63.
52. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S and Yki-Jarvinen H (2008). Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology, 135: 122-130.
53. Li RX, Chen HB, Tu K, Zhao SL, Zhou H, Li SJ, Dai J, Li QR, Nie S, Li YX, Jia WP, Zeng R and Wu JR (2008). Localized-statistical quantification of human serum proteome associated with type 2 diabetes. PLoS One, 3: e3224.
54. Lim MS and Elenitoba-Johnson KS (2004). Proteomics in pathology research. Lab. Invest., 84: 1227-1244.
55. Ling C and Groop L (2009). Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes, 58: 2718-2725.
56. Liu J, Carrillo B, Yanofsky C, Beaudrie C, Morales F and Kearney R (2005). A novel approach to speed up peptide sequencing via MS/MS spectra analysis. Conf. Proc. IEEE Eng. Med. Biol. Soc., 4: 4441-4444.
57. Lozano-Nuevo JJ, Estrada-Garcia T, Vargas-Robles H, Escalante-Acosta BA and Rubio-Guerra AF (2011). Correlation between circulating adhesion molecules and resistin levels in hypertensive type-2 diabetic patients. Inflamm. Allergy Drug Targets, 10: 27-31.
58. Madsbad S, Schmitz O, Ranstam J, Jakobsen G and Matthews DR (2004). Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care, 27: 1335-1342.
59. Malandrino N and Smith RJ (2011). Personalized medicine in diabetes. Clin. Chem., 57: 231-240.
60. Mann M, Hendrickson RC and Pandey A (2001). Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem., 70: 437-473.
61. Maris M, Overbergh L and Mathieu C (2008). Type 2 diabetes: Gaining insight into the disease process using proteomics. Proteomics Clin. Appl., 2: 312-326.
62. Marko-Varga G and Fehniger TE (2004). Proteomics and disease - The challenges for technology and discovery. J. Proteome Res., 3: 167-178.
63. Martin SS, Qasim A and Reilly MP (2008). Leptin resistance: A possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J. Am. Coll. Cardiol., 52: 1201-1210.
64. Maynard JD, Rohrscheib M, Way JF, Nguyen CM and Ediger MN (2007). Noninvasive type 2 diabetes screening: Superior sensitivity to fasting plasma glucose and A1C. Diabetes Care, 30: 1120-1124.
65. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, Wilson PW, D'Agostino RB, Sr. and Cupples LA (2008). Genotype score in addition to common risk factors for prediction of type 2 diabetes. N. Engl. J. Med., 359: 2208-2219.
66. Memisogullari R and Bakan E (2004). Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J. Diabetes Complications, 18: 193-197.
67. Merrell K, Southwick K, Graves SW, Esplin MS, Lewis NE and Thulin CD (2004). Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J. Biomol. Tech., 15: 238-248.
68. Miller KJ, Bowsher RR, Celniker A, Gibbons J, Gupta S, Lee JW, Swanson SJ, Smith WC and Weiner RS (2001). Workshop on bioanalytical methods validation for macromolecules: Summary report. Pharm. Res., 18: 1373-1383.
69. Mischak H, Julian BA and Novak J (2007). Highresolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine. Proteomics Clin. Appl., 1: 792.
70. Moller DE (2001). New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 414: 821-827.
71. Naseeb U, Shafqat J, Jagerbrink T, Zarina S, Alvestrand A, Jornvall H and Axelsson J (2008). Proteome patterns in uremic plasma. Blood Purif, 26: 561-568.
72. Okada S, List EO, Sankaran S and Kopchick JJ (2010). Plasma protein biomarkers correlated with the development of diet-induced Type 2 diabetes in mice. Clin. Proteomics, 6: 6-17.
73. Ordovas JM and Corella D (2004). Nutritional genomics. Annu. Rev. Genomics Hum. Genet., 5: 71-118.
74. Ouzounian M, Lee DS, Gramolini AO, Emili A, Fukuoka M and Liu PP (2007). Predict, prevent and personalize: Genomic and proteomic approaches to cardiovascular medicine. Can. J. Cardiol., 23(Suppl A): 28A-33A.
75. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, Su Q, McGrath AM, Estock MA, Parmar PP, Zhao M, Huang ST, Zhou J, Wang F, Esquer-Blasco R, Anderson NL, Taylor J and Steiner S (2003). The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on twodimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics, 3: 1345-1364.
76. Pisitkun T, Johnstone R and Knepper MA (2006). Discovery of urinary biomarkers. Mol. Cell Proteomics, 5: 1760-1771.
77. Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, Erickson SK and Najjar SM (2002). CEACAM1 regulates insulin clearance in liver. Nat. Genet., 30: 270-276.
78. Qian WJ, Jacobs JM, Liu T, Camp DG, 2nd and Smith RD (2006). Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell Proteomics, 5: 1727-1744.
79. Rabilloud T (2002). Two-dimensional gel electrophoresis in proteomics: Old, old fashioned, but it still climbs up the mountains. Proteomics, 2: 3-10.
80. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, Mehigh RJ, Cockrill SL, Scott GB, Tammen H, Schulz-Knappe P, Speicher DW, Vitzthum F, Haab BB, Siest G and Chan DW (2005). HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics, 5: 3262-3277.
81. Rai AJ and Vitzthum F (2006). Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: Implications for clinical proteomics. Expert Rev. Proteomics, 3: 409-426.
82. Rao PV, Lu X, Standley M, Pattee P, Neelima G, Girisesh G, Dakshinamurthy KV, Roberts CT, Jr. and Nagalla SR (2007). Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care, 30: 629-637.
83. Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, Roberts CT and Nagalla SR (2009). Proteomic identification of salivary biomarkers of type-2 diabetes. J. Proteome Res., 8: 239-245.
84. Rathmann W and Giani G (2004). Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 27: 2568-2569 (author reply 2569).
85. Riaz S, Alam SS and Akhtar MW (2010a). Proteomic identification of human serum biomarkers in diabetes mellitus type 2. J. Pharm. Biomed. Anal., 51: 1103-1107.
86. Riaz S, Alam SS, Srai SK, Skinner V, Riaz A and Akhtar MW (2010b). Proteomic identification of human urinary biomarkers in diabetes mellitus type 2. Diabetes Technol. Ther., 12: 979-988.
87. Riaz S, Skinner V and Srai SK (2011). Effect of high dose thiamine on the levels of urinary protein biomarkers in diabetes mellitus type 2. J. Pharm. Biomed. Anal., 54: 817-825.
88. Rosen ED and Spiegelman BM (2006). Adipocytes as regulators of energy balance and glucose homeostasis. Nature, 444: 847-853.
89. Ross SA, Gulve EA and Wang M (2004). Chemistry and biochemistry of type 2 diabetes. Chem. Rev., 104: 1255-1282.
90. Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A and Maahs DM (2008). The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin. Appl., 2: 997-1007.
91. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K and Blankenberg S (2010). Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One, 5: e10100.
92. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D and Davidson MB (2008). A new look at screening and diagnosing diabetes mellitus. J. Clin. Endocrinol. Metab., 93: 2447-2453.
93. Scott EM, Carter AM and Findlay JB (2005). The application of proteomics to diabetes. Diab. Vasc. Dis. Res., 2: 54-60.
94. Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE, Berger PB and Somers VK (2004). Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation, 109: 2181-2185.
95. Steinberger J and Daniels SR (2003). Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation, 107: 1448-1453.
96. Suh SH, Paik IY and Jacobs K (2007). Regulation of blood glucose homeostasis during prolonged exercise. Mol. Cells, 23: 272-279.
97. Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR and Hill JO (2005). Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care, 28: 1599-1603.
98. Sundsten T, Eberhardson M, Goransson M and Bergsten P (2006). The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci., 4: 22.
99. Sundsten T and Ortsater H (2009). Proteomics in diabetes research. Mol. Cell Endocrinol., 297: 93-103.
100. Sundsten T, Ostenson CG and Bergsten P (2008a). Serum protein patterns in newly diagnosed type 2 diabetes mellitus - Influence of diabetic environment and family history of diabetes. Diabetes Metab. Res. Rev., 24: 148-154.
101. Sundsten T, Zethelius B, Berne C and Bergsten P (2008b). Plasma proteome changes in subjects with Type 2 diabetes mellitus with a low or high early insulin response. Clin. Sci. (Lond), 114: 499-507.
102. Tammen H, Schulte I, Hess R, Menzel C, Kellmann M, Mohring T and Schulz-Knappe P (2005). Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display. Proteomics, 5: 3414-3422.
103. T ang HY, Ali-Khan N, Echan LA, Levenkova N, Rux JJ and Speicher DW (2005). A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics, 5: 3329-3342.
104. Thakur SS, Geiger T, Chatterjee B, Bandilla P, Frohlich F, Cox J and Mann M (2011). Deep and highly sensitive proteome coverage by LC-MS/MS without prefractionation. Mol. Cell Proteomics, 10: M110 003699.
105. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP and Veenstra TD (2003). Characterization of the low molecular weight human serum proteome. Mol. Cell Proteomics, 2: 1096-1103.
106. Tucholska M, Bowden P, Jacks K, Zhu P, Furesz S, Dumbrovsky M and Marshall J (2009). Human serum proteins fractionated by preparative partition chromatography prior to LC-ESI-MS/MS. J. Proteome Res., 8: 1143-1155.
107. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen- Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V and Uusitupa M (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med., 344: 1343-1350.
108. Van den Berghe G (2004). How does blood glucose control with insulin save lives in intensive care? J. Clin. Invest., 114: 1187-1195.
109. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE and Neal B (2010). The global burden of diabetes and its complications: an emerging pandemic. Eur. J. Cardiovasc. Prev. Rehabil., 17(Suppl 1): S3-S8.
110. Villegas R, Shu XO, Li H, Yang G, Matthews CE, Leitzmann M, Li Q, Cai H, Gao YT and Zheng W (2006). Physical activity and the incidence of type 2 diabetes in the Shanghai women's health study. Int. J. Epidemiol., 35: 1553-1562.
111. Wang J, Li D, Dangott LJ and Wu G (2006). Proteomics and its role in nutrition research. J. Nutr., 136: 1759-1762.
112. Wang Z, Park K, Comer F, Hsieh-Wilson LC, Saudek CD and Hart GW (2009). Site-specific GlcNAcylation of human erythrocyte proteins: Potential biomarker(s) for diabetes. Diabetes, 58: 309-317.
113. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R and John A (2007). Screening for type 2 diabetes: Literature review and economic modelling. Health Technol. Assess., 11: iii-iv, ix-xi, 1-125.
114. Weill J, Vanderbecken S and Froguel P (2004). Understanding the rising incidence of type 2 diabetes in adolescence. Arch. Dis. Child, 89: 502-504.
115. Wild S, Roglic G, Green A, Sicree R and King H (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27: 1047-1053.
116. Wu H, Yu Z, Qi Q, Li H, Sun Q and Lin X (2011). Joint analysis of multiple biomarkers for identifying type 2 diabetes in middle-aged and older Chinese: A crosssectional study. BMJ Open, 1: e000191.
117. Zhang SX, Sun H, Sun WJ, Jiao GZ and Wang XJ (2010). Proteomic study of serum proteins in a type 2 diabetes mellitus rat model by Chinese traditional medicine Tianqi Jiangtang Capsule administration. J. Pharm. Biomed. Anal., 53: 1011-1014.